Please use this identifier to cite or link to this item:
Title: Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers
Authors: Das, K. 
Lorena, P.D.N.
Kuan Ng, L.
Shen, L.
Lim, D.
Yun Siow, W.
Narasimhan, K.
Teh, M.
Choolani, M.
Putti, T.C.
Salto-Tellez, M. 
Keywords: Androgen receptor
Breast cancer
Oestrogen receptor
Ovarian cancer
Progesterone receptor
Prostate cancer
Issue Date: Oct-2010
Citation: Das, K., Lorena, P.D.N., Kuan Ng, L., Shen, L., Lim, D., Yun Siow, W., Narasimhan, K., Teh, M., Choolani, M., Putti, T.C., Salto-Tellez, M. (2010-10). Aurora-A expression, hormone receptor status and clinical outcome in hormone related cancers. Pathology 42 (6) : 540-546. ScholarBank@NUS Repository.
Abstract: Aims: We investigated the correlation between protein expression of Aurora-A with hormone receptor expression and clinicopathological parameters in ovarian, breast and prostate cancer. Methods: Subcellular expression of Aurora-A, and androgen receptor (AR), oestrogen receptor (ER) and progesterone receptor (PR) expression, were examined by immunohistochemistry in human tissue microarrays of the three cancer types and by Western blot in cancer cell lines and selected patient tissues. Results: Subgroups of all three cancer types exhibited both nuclear and cytoplasmic expression of Aurora-A. Nuclear presence of Aurora-A was observed in ER positive and negative breast cancer cell lines and tissues. Eighteen of the 126 (14) tumour tissues that showed nuclear expression of Aurora-A were strongly associated with ER and PR positive breast tumours (p0.001). Cytoplasmic expression of AR and Aurora-A was strongly associated in prostate cancer tissues (45 versus 0, p0.015). Ovarian tumours (n45) with Aurora-A nuclear expression had decreased patient survival (mean survival, 29.5 versus 106.7 months; p<0.0005) and showed a significant association with recurrence-free survival (mean survival 19.7 versus 95.9 months; p0.002). Conclusion: Association between nuclear Aurora-A with hormone receptors in breast cancer and with poor clinical outcome in ovarian cancer suggests the significance of active Aurora-A in disease initiation and progression. © 2010 The Royal College of Pathologists of Australasia.
Source Title: Pathology
ISSN: 00313025
DOI: 10.3109/00313025.2010.508789
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Aug 16, 2022


checked on Aug 16, 2022

Page view(s)

checked on Aug 18, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.